一代EGFR-TKI联合脑放疗在EGFR敏感突变的晚期非小细胞肺癌脑转移患者中的疗效及安全性分析  

Efficacy and safety of first-generation EGFR-TKI in combination with brain radiotherapy in patients with brain metastases from advanced NSCLC harboring EGFR-sensitive mutations

作　　者：黄潞[1] 陈康彪[1] 叶妍妍 劳逸[1] 王永领[1] 何江涛[1] 汪金锋[1] HUANG Lu;CHEN Kangbiao;YE Yanyan;LAO Yi;WANG Yongling;HE Jiangtao;WANG Jinfeng(Fourth Disease District of the Department of Medical Oncology,Guangdong Nongken Central Hospital,Guangdong,Zhanjiang 524000,China)

机构地区：[1]广东省农垦中心医院肿瘤内科四区,广东湛江524000

出　　处：《中国医药科学》2022年第20期34-37,共4页China Medicine And Pharmacy

基　　金：广东省湛江市非资助科技攻关计划项目(2021B01431)。

摘　　要：目的探究一代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)联合脑放疗在表皮生长因子受体(EGFR)敏感突变的晚期非小细胞肺癌脑转移患者中的疗效及安全性。方法选取2017年1月至2019年7月广东省农垦中心医院肿瘤内科四区收治的86例晚期非小细胞肺癌脑转移患者为研究对象,采用随机数表法分为观察组(n=43)与对照组(n=43),对照组通过单纯的一代EGFR-TKI靶向治疗进行干预,观察组需在一代EGFR-TKI靶向疗法的基础上通过脑放疗进行干预。在经过上述方案治疗后,对治疗过程中的相关数据进行统计,对比两组患者干预后的治疗效果、生存情况以及不良反应发生情况。结果观察组客观缓解率为86.05%优于对照组的67.44%,差异有统计学意义(P<0.05),对比两组患者的生存情况发现,观察组的各项指标高于对照组,差异有统计学意义(P<0.05),此外,对比两组患者的不良反应发生率,发现观察组不良反应发生率为13.95%低于对照组的34.88%,差异有统计学意义(P<0.05)。结论经一代EGFR-TKI联合脑放疗干预治疗后,患者能获得很好的效果,生存率高,治疗期间有着较高的安全性,治疗认可度高,具备推广使用价值。Objective To investigate the efficacy and safety of a combination of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)and brain radiotherapy in patients with brain metastases from advanced non-small cell lung cancer(NSCLC)harboring EGFR-sensitive mutations.Methods A total of 86 patients with brain metastases from advanced NSCLC admitted to the Fourth Disease District of the Department of Medical Oncology of Guangdong Nongken Central Hospital from January 2017 to July 2019 were selected as study subjects,and they were divided into the observation group(n=43)and the control group(n=43)according to the random number table method.The control group was intervened with first-generation EGFR-TKI targeting therapy alone,while the observation group was intervened with brain radiotherapy on the basis of first-generation EGFR-TKI targeting therapy.Compare the efficacy,survival time and the occurrence of adverse reactions in the two groups.Results The objective remission rate of the observation group was 86.05%,which was better than 67.44%of the control group,and the difference was s tatistically significant(P<0.05).Comparing the survival of the two groups of patients,it was found that the indicators of the observation group were higher than those of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 13.95%lower than 34.88%in the control group,and the difference was statistically significant(P<0.05).Conclusion Sound efficacy,high survival rate and high safety are observed,and high recognition of the treatment is obtained from patients treated with first-generation EGFR-TKI combined with brain radiotherapy.Therefore,this combined treatment is worthy of promotion and application.

关 键 词：表皮生长因子受体酪氨酸激酶抑制剂 放疗 肺癌 脑转移 

分 类 号：R734.2[医药卫生—肿瘤]